Incidental Diagnosis After Cardiac Surgery Leads International Patient To HCGMCC For World-Class Treatment

Nashik, July 07: In a remarkable journey spanning continents and specialties, HCG Manavata Cancer Centre (HCGMCC) Nashik, successfully treated 62 year old Mr Bosco Daniel, a Dubai based hotelier, for prostate cancer using advanced robotic assisted surgery. What began as a sudden cardiac emergency in India quickly became a life altering moment when routine investigations revealed an incidental diagnosis of prostate cancer. After exploring treatment options across leading metros, Bosco chose Nashik, and never looked back. When he arrived in India for an angioplasty to address his cardiac condition, a subsequent evaluation during hospitalization uncovered early stage prostate cancer. This presented a clinical dilemma – after angioplasty, surgery cannot be performed for at least six months due to the high risk of stent thrombosis. To bridge this gap, Dr Raj Nagarkar and his team administered hormone therapy, a carefully timed intervention that controlled the cancer while allowing Bosco’s heart to heal.

“Bosco’s case required careful coordination between cardiac and cancer care. Regarding his health, there were two challenges viz. how to address his prostate cancer without compromising his heart health. We used hormone therapy for 3 to 6 months, which kept the cancer in check while his cardiac condition stabilised. Once the safe window arrived, we proceeded with robotic assisted surgery. This is the importance of individualized treatment planning, where every decision is made in the patient’s best interest rather than following a one-size-fits-all approach. Bosco recovered exceptionally well and returned to his country within a fortnight,” says Prof Dr Raj Nagarkar, Chief of Surgical Oncology & Robotic Services and Managing Director, KIMS Manavata Hospitals, HCG Manavata Cancer Centre and Six Sigma, Nashik.

The minimally invasive robotic procedure was completed successfully, allowing the patient to recover remarkably quickly. He was able to walk and resume basic activities within just two days, was discharged after three days in hospital, and returned to Dubai within two weeks. Following removal of the urinary catheter a week later, he regained complete bladder control and, importantly, his final histopathology report confirmed that no further treatment such as radiation therapy was required.

“One of the biggest concerns among men diagnosed with prostate cancer is the fear of losing urinary control after surgery. Thanks to advances in robotic assisted surgery and growing surgical expertise, these risks have reduced significantly. Robotic surgery offers unmatched precision, enabling better preservation of vital nerves and structures, resulting in faster recovery, minimal pain, shorter hospital stay and excellent functional outcomes. In Mr Bosco’s case, he regained complete bladder control soon after catheter removal and was able to return to his normal life without requiring any additional treatment. Cases like these reinforce why robotic surgery has become one of the preferred treatment options for appropriately selected patients with localized prostate cancer,” concludes Dr Nagarkar.

Now back in Dubai, Bosco continues to remain under the care of Dr Nagarkar and his team through regular tele-consultations and virtual follow ups, reflecting HCGMCC’s commitment to providing seamless continuity of care for international patients.

Nashik, Oct Nashik, Oct 09: Dr Raj Nagarkar, MD & Chief of Surgical Oncology & Robotic Services of HCG Manavata Cancer Centre (HCGMCC) has become the first and only Indian doctor appointed to the Advisory Board of Cambridge Medical Robotics (CMR). During his two-year term, Dr Nagarkar will focus on advocating for accessible and affordable healthcare solutions for patients in India. At the upcoming Global Advisory Board meeting in Cambridge later this month, he will participate in discussions on the latest advancements in robotic surgery and instrumentation.

Dr Raj Nagarkar, a specialist oncologist with over 23 years of experience, has performed more than 65,000 surgeries and treated over 2,50,000 cancer patients. He also holds a world record for completing over 1,100 successful robotic surgeries.

“It is a privilege and honour to join Cambridge Medical Robotics’ advisory board, and I am grateful to its leadership for this opportunity. My role will be to represent the Indian healthcare landscape, pushing for advancements and customizations in surgical technology that benefit patients. The agenda for the meeting includes exploring new developments in robotics, engaging in doctor and patient education, interacting with engineers for further innovations, and ensuring that this technology becomes widely accessible globally,” says Dr Raj Nagarkar.

CMR Surgical, a UK-based medical technology firm, specializes in robotic surgical systems. Founded in 2014 and headquartered in Cambridge, England, CMR is renowned for developing Versius, a next-generation minimally invasive robotic surgical system that enhances precision and flexibility during surgeries. The company aims to make robotic-assisted surgery both accessible and affordable for healthcare providers worldwide.

“India is an emerging market for robotic healthcare solutions, with a large population and increasing demands. Technology is becoming integral to healthcare in the country. CMR, which already has over 40 robot installations in India, is keen to expand its footprint further. This expansion will make technology-driven healthcare more accessible and affordable for Indian patients, while also ensuring improved surgical outcomes,” concludes Dr Nagarkar.